JP2022115932A5 - - Google Patents

Download PDF

Info

Publication number
JP2022115932A5
JP2022115932A5 JP2022074779A JP2022074779A JP2022115932A5 JP 2022115932 A5 JP2022115932 A5 JP 2022115932A5 JP 2022074779 A JP2022074779 A JP 2022074779A JP 2022074779 A JP2022074779 A JP 2022074779A JP 2022115932 A5 JP2022115932 A5 JP 2022115932A5
Authority
JP
Japan
Prior art keywords
cell
vector
expression
optionally
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022074779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022115932A (ja
JP7394914B2 (ja
Filing date
Publication date
Priority claimed from JP2020559043A external-priority patent/JP7068498B2/ja
Application filed filed Critical
Publication of JP2022115932A publication Critical patent/JP2022115932A/ja
Publication of JP2022115932A5 publication Critical patent/JP2022115932A5/ja
Priority to JP2023200890A priority Critical patent/JP7763824B2/ja
Application granted granted Critical
Publication of JP7394914B2 publication Critical patent/JP7394914B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022074779A 2018-01-12 2022-04-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物 Active JP7394914B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023200890A JP7763824B2 (ja) 2018-01-12 2023-11-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2018-0004238 2018-01-12
KR20180004238 2018-01-12
JP2020559043A JP7068498B2 (ja) 2018-01-12 2019-01-10 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物
PCT/IB2019/050194 WO2019138354A1 (en) 2018-01-12 2019-01-10 Enhanced immune cells using dual shrna and composition including the same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020559043A Division JP7068498B2 (ja) 2018-01-12 2019-01-10 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023200890A Division JP7763824B2 (ja) 2018-01-12 2023-11-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Publications (3)

Publication Number Publication Date
JP2022115932A JP2022115932A (ja) 2022-08-09
JP2022115932A5 true JP2022115932A5 (cg-RX-API-DMAC7.html) 2023-01-10
JP7394914B2 JP7394914B2 (ja) 2023-12-08

Family

ID=67218229

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020559043A Active JP7068498B2 (ja) 2018-01-12 2019-01-10 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物
JP2022074779A Active JP7394914B2 (ja) 2018-01-12 2022-04-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物
JP2023200890A Active JP7763824B2 (ja) 2018-01-12 2023-11-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020559043A Active JP7068498B2 (ja) 2018-01-12 2019-01-10 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023200890A Active JP7763824B2 (ja) 2018-01-12 2023-11-28 二重shRNAを用いて強化された免疫細胞及びそれを含む組成物

Country Status (14)

Country Link
US (4) US11679129B2 (cg-RX-API-DMAC7.html)
EP (2) EP3737765B2 (cg-RX-API-DMAC7.html)
JP (3) JP7068498B2 (cg-RX-API-DMAC7.html)
KR (2) KR102327512B1 (cg-RX-API-DMAC7.html)
CN (1) CN111801421B (cg-RX-API-DMAC7.html)
AU (2) AU2019206425B2 (cg-RX-API-DMAC7.html)
CA (1) CA3088234A1 (cg-RX-API-DMAC7.html)
DK (1) DK3737765T4 (cg-RX-API-DMAC7.html)
ES (2) ES2908324T5 (cg-RX-API-DMAC7.html)
FI (1) FI3737765T4 (cg-RX-API-DMAC7.html)
PL (1) PL3737765T5 (cg-RX-API-DMAC7.html)
PT (1) PT3737765T (cg-RX-API-DMAC7.html)
SG (1) SG11202006606YA (cg-RX-API-DMAC7.html)
WO (1) WO2019138354A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210069241A1 (en) * 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
KR102327512B1 (ko) 2018-01-12 2021-11-17 주식회사 큐로셀 이원 shrna를 이용한 향상된 면역 세포 및 이를 포함하는 조성물
CN109485732B (zh) * 2018-12-20 2021-09-24 四川大学华西医院 基因工程修饰的双靶点嵌合抗原受体及其用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN114127268A (zh) * 2019-05-02 2022-03-01 塞利亚德股份公司 具有多重化的抑制性rna的细胞
WO2021009701A1 (en) * 2019-07-17 2021-01-21 Curocell Inc. Enhanced immune cells using dual shrna and composition including the same
TW202118792A (zh) * 2019-07-26 2021-05-16 美商健生生物科技公司 抗hk2嵌合抗原受體(car)
EP4061927A4 (en) * 2019-11-20 2024-11-13 Cartherics Pty. Ltd. METHOD FOR PROVIDING IMMUNE CELLS WITH ENHANCED FUNCTION
CN115362256A (zh) 2020-02-07 2022-11-18 因特利亚治疗公司 用于激肽释放酶(klkb1)基因编辑的组合物和方法
GB202008688D0 (en) * 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
WO2022011065A1 (en) * 2020-07-07 2022-01-13 The Nemours Foundation Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer
CN114075562A (zh) * 2021-03-10 2022-02-22 北京肿瘤医院(北京大学肿瘤医院) Mage-c3抑制剂及其作为制备治疗和/或预防食管鳞状细胞癌药物的用途
CN113416729B (zh) * 2021-05-18 2022-11-22 遵义医科大学附属医院 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用
CN113403208A (zh) * 2021-06-15 2021-09-17 江西科技师范大学 高效鉴定米曲霉CRISPR/Cas9突变体的方法
AU2022299474A1 (en) * 2021-06-23 2023-12-21 Versameb Ag Compositions and methods for modulating expression of genes
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
WO2023147776A1 (en) * 2022-02-07 2023-08-10 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
EP4282963A1 (en) 2022-05-23 2023-11-29 Eberhard Karls Universität Tübingen, Medizinische Fakultät Nucleic acid modified biological cell with expansion-dependent gene expression
CN114836428B (zh) * 2022-06-08 2024-03-26 华东师范大学 一种tigit基因干扰的嵌合抗原受体nk细胞及其应用
WO2023238103A1 (en) * 2022-06-10 2023-12-14 Curocell Inc. Car-t therapy for treating cancer
CN116983322B (zh) * 2022-09-15 2026-04-07 圣诺生物医药技术(苏州)有限公司 用于治疗肺癌、胰腺癌、肝癌和结直肠癌的小核酸干扰药物
TW202442689A (zh) 2023-03-03 2024-11-01 美商亞森諾生物科學公司 靶向psma及ca9之系統
EP4698648A1 (en) * 2023-04-18 2026-02-25 uniQure biopharma B.V. Gene delivery vehicles comprising rna and antibodies
CN116515836B (zh) * 2023-05-09 2023-12-01 中国人民解放军军事科学院军事医学研究院 抑制MerTK表达的shRNA、腺相关病毒及其应用
CN117587014B (zh) * 2023-11-24 2025-01-24 上海恩凯细胞技术有限公司 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US20070036773A1 (en) * 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
US20080293142A1 (en) 2007-04-19 2008-11-27 The Board Of Regents For Oklahoma State University Multiple shRNA Expression Vectors and Methods of Construction
WO2008134646A2 (en) 2007-04-26 2008-11-06 University Of Iowa Research Foundation Rna interference suppression of neurodegenerative diseases and methods of use thereof
ES2739804T3 (es) 2011-02-12 2020-02-04 Univ Iowa Res Found Compuestos terapéuticos
MX2014001222A (es) 2011-07-29 2014-09-15 Univ Pennsylvania Receptores coestimuladores de cambio.
KR20140060541A (ko) * 2011-09-16 2014-05-20 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암을 치료하기 위한 rna 조작된 t 세포
SG11201505896YA (en) 2013-02-20 2015-09-29 Novartis Ag Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
CA2912389C (en) 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
ES2918501T3 (es) * 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
CN122399016A (zh) * 2014-03-15 2026-07-17 诺华股份有限公司 使用嵌合抗原受体治疗癌症
SG10202109752XA (en) * 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
AU2015264263B2 (en) 2014-05-20 2021-08-05 University Of Iowa Research Foundation Huntington's disease therapeutic compounds
KR102546296B1 (ko) 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
ES2592578B1 (es) 2015-05-07 2017-12-18 Dode, S.A. Mejoras introducidas en la patente de invención "Procedimiento para el tratamiento de granos de maíz destinados a la obtención de palomitas de maíz por medio de aparatos microondas y producto obtenido"
US11242375B2 (en) * 2015-09-04 2022-02-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
ES2987957T3 (es) * 2015-11-23 2024-11-18 Novartis Ag Vectores de transferencia lentivirales optimizados y usos de los mismos
CN108463885A (zh) 2015-12-11 2018-08-28 罗姆股份有限公司 半导体装置
CN106967685B (zh) 2016-01-13 2020-06-02 北京马力喏生物科技有限公司 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途
CN106967681B (zh) 2016-01-13 2020-06-05 北京马力喏生物科技有限公司 治疗脑胶质母细胞瘤的治疗组合物
EP3219800A1 (en) * 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
US11111505B2 (en) * 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
WO2018012895A1 (ko) * 2016-07-14 2018-01-18 주식회사 큐로셀 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물
AU2017326748A1 (en) * 2016-09-14 2019-04-11 Benitec Biopharma Limited Reagents for producing T-cells with non-functional T-cell receptors (TCRs) compositions comprising same and use thereof
US12447213B2 (en) * 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
CN107058390A (zh) * 2017-01-17 2017-08-18 上海交通大学医学院附属第九人民医院 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用
EP3585398A4 (en) * 2017-02-23 2020-08-19 Board of Regents of the University of Nebraska COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
KR102327512B1 (ko) 2018-01-12 2021-11-17 주식회사 큐로셀 이원 shrna를 이용한 향상된 면역 세포 및 이를 포함하는 조성물
CN110904045A (zh) 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
WO2021009701A1 (en) 2019-07-17 2021-01-21 Curocell Inc. Enhanced immune cells using dual shrna and composition including the same

Similar Documents

Publication Publication Date Title
JP7708436B2 (ja) 核酸を細胞に送達するための組成物および方法
Zhukovsky et al. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
JP2023542348A5 (cg-RX-API-DMAC7.html)
US10604740B2 (en) Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein
JP2022512882A5 (cg-RX-API-DMAC7.html)
FI3737765T4 (fi) Parannettuja immuunisoluja käyttämällä kahta shRNA:ta ja niitä sisältäviä koostumuksia
HRP20240494T1 (hr) Kimerni antigenski receptori specifični za bcma i njihove upotrebe
RU2015117237A (ru) Химерные антигенные рецепторы м971
JP2020513829A5 (cg-RX-API-DMAC7.html)
CN106967681B (zh) 治疗脑胶质母细胞瘤的治疗组合物
RU2016129125A (ru) Химерные рецепторы антигена против мезотелина человека и их применение
AU2020264760A1 (en) Cells with multiplexed inhibitory RNA
CN114230670A (zh) 靶向血液恶性肿瘤之嵌合抗原受体(car)、其组合物及使用方法
JP2017522879A5 (cg-RX-API-DMAC7.html)
US11639496B2 (en) Reducing fratricide of immune cells expressing NKG2D-based receptors
JP2022509017A (ja) 抗ptk7免疫細胞癌療法
TWI915404B (zh) 用於治療egfr陽性癌症之組合物及方法
US20240190998A1 (en) Compositions and methods for delivery of nucleic acids to cells
US20230265214A1 (en) Compositions and methods for delivery of nucleic acids to cells
JP2023540041A5 (cg-RX-API-DMAC7.html)
US20220380774A1 (en) Asymmetric sirna inhibiting expression of pd-1
CN109554349B (zh) Pd-1基因表达沉默的工程化免疫细胞
JP2021517454A5 (cg-RX-API-DMAC7.html)
JP2023541456A5 (cg-RX-API-DMAC7.html)
JP2022532998A (ja) 選択的イントロンのスプライシングを調節するための方法及び組成物